Medlive Technology Co., Ltd. (HK:2192)
:2192
Want to see HK:2192 full AI Analyst Report?
Top Page
Medlive Technology Co., Ltd.
(2192)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$7.50
▼(-23.70% Downside)
Action:Downgraded
Date:04/25/26
The score is driven primarily by strong financial fundamentals—especially high profitability and very low balance-sheet risk—partly offset by the 2025 revenue decline and weaker cash conversion. Technicals are a headwind due to a clear downtrend versus key moving averages, while valuation is moderately supportive with a reasonable P/E and a ~3.2% dividend yield.
Positive Factors
Platform business model and repeat client revenue
Medlive’s core platform monetizes targeted physician-facing content, CME-style education and campaign services sold to pharma and healthcare firms. That model supports recurring, contractable revenue and customer stickiness as client campaigns and repeat sponsorships persist, underpinning stable revenue potential over months to years.
Negative Factors
Material 2025 revenue decline and growth volatility
A sharp top-line reversal undermines revenue predictability and signals client spending volatility or lost engagements. For a platform relying on repeat pharma campaigns, such a decline can compress forward visibility, limit reinvestment, and stress client retention initiatives, making medium-term recovery and planning more uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform business model and repeat client revenue
Medlive’s core platform monetizes targeted physician-facing content, CME-style education and campaign services sold to pharma and healthcare firms. That model supports recurring, contractable revenue and customer stickiness as client campaigns and repeat sponsorships persist, underpinning stable revenue potential over months to years.
Read all positive factors
Medlive Technology Co., Ltd. (2192) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.93B
Dividend Yield2.72%
Average Volume (3M)1.46M
Price to Earnings (P/E)12.6
Beta (1Y)1.32
Revenue Growth15.04%
EPS Growth5.57%
CountryHK
Employees747
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.45
Shares Outstanding740,114,140
10 Day Avg. Volume901,132
30 Day Avg. Volume1,461,578
Financial Highlights & Ratios
PEG Ratio2.75
Price to Book (P/B)1.32
Price to Sales (P/S)10.00
P/FCF Ratio52.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$13.10Price Target Upside33.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.49
Revenue Forecast (FY)HK$753.08M
Medlive Technology Co., Ltd. Business Overview & Revenue Model
Company Description
Medlive Technology Co., Ltd., along with its affiliated entities, manages a digital platform tailored for medical professionals, serving both the Chinese mainland and international markets. Through its comprehensive platform, the company delivers ...
How the Company Makes Money
Medlive generates revenue primarily by monetizing its online physician platform and related digital healthcare infrastructure. Key revenue streams include: (1) digital marketing and promotion services for pharmaceutical and medical device companie...
Medlive Technology Co., Ltd. Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
92
Very Positive
Cash Flow
61
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 642.15M | 558.46M | 412.00M | 314.05M | 284.44M |
| Gross Profit | 385.44M | 327.22M | 251.34M | 212.74M | 200.73M |
| EBITDA | 174.99M | 121.35M | 262.86M | 144.56M | 76.61M |
| Net Income | 334.34M | 315.15M | 242.30M | 117.32M | 40.62M |
Balance Sheet | |||||
| Total Assets | 5.16B | 5.11B | 4.89B | 4.60B | 4.12B |
| Cash, Cash Equivalents and Short-Term Investments | 3.72B | 4.15B | 4.40B | 4.22B | 3.91B |
| Total Debt | 10.11M | 22.63M | 8.19M | 11.26M | 13.17M |
| Total Liabilities | 230.01M | 253.56M | 248.61M | 171.31M | 143.37M |
| Stockholders Equity | 4.87B | 4.80B | 4.60B | 4.40B | 3.95B |
Cash Flow | |||||
| Free Cash Flow | 121.70M | 87.44M | 69.34M | 69.70M | 42.47M |
| Operating Cash Flow | 134.54M | 108.32M | 101.87M | 77.19M | 44.43M |
| Investing Cash Flow | 220.68M | 111.02M | -634.95M | -3.59B | -50.54M |
| Financing Cash Flow | -201.45M | -197.89M | -133.13M | -22.38M | 3.79B |
Medlive Technology Co., Ltd. Technical Analysis
Negative
9.83
Price Trends
8.03
Negative
8.64
Negative
9.97
Negative
Market Momentum
-0.34
Positive
23.46
Positive
12.30
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2192, the sentiment is Negative. The current price of 9.83 is above the 20-day moving average (MA) of 7.32, above the 50-day MA of 8.03, and below the 200-day MA of 9.97, indicating a bearish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 23.46 is Positive, neither overbought nor oversold. The STOCH value of 12.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2192.
Medlive Technology Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$4.93B | 12.61 | 6.89% | 2.72% | 15.04% | 5.57% | |
60 Neutral | HK$62.40B | 10.16 | 7.64% | 2.67% | 6.45% | 35.60% | |
57 Neutral | HK$51.12B | 6.19 | 8.70% | 3.75% | -1.57% | 1.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$680.40M | 12.69 | 7.66% | 8.03% | -1.11% | -13.09% | |
41 Neutral | HK$735.18M | -4.25 | 480.37% | ― | -17.39% | -45.76% | |
40 Underperform | HK$1.14B | 27.95 | 1.09% | 3.81% | -10.71% | -87.93% |
* Healthcare Sector Average
HK:2192
Medlive Technology Co., Ltd.
6.66
-8.33
-55.56%
HK:0673
China Health Group
0.53
0.31
140.91%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.93
0.89
8.09%
HK:1099
Sinopharm Group Co
16.38
-2.06
-11.17%
HK:1931
IVD Medical Holding Limited
0.70
-1.32
-65.35%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
6.30
-0.29
-4.34%
Medlive Technology Co., Ltd. Corporate Events
Medlive Shareholders Approve All Resolutions at 2026 AGM, Back Governance and Capital Mandates
May 15, 2026
Medlive Technology Co., Ltd. reported that all resolutions at its annual general meeting held in Beijing on 15 May 2026 were duly passed by poll, with shareholder participation covering the company’s entire issued share capital eligible to v...
Medlive Details Audit Committee Rationale for Appointing Deloitte as New Auditor
May 5, 2026
Medlive Technology Co., Ltd. has issued a supplemental announcement detailing its Audit Committee’s assessment of Deloitte as the proposed new auditor, following an earlier notice of auditor change. The committee highlighted Deloitte’s...
Medlive Sets 2026 AGM to Approve Dividend, Board Slate and Capital Mandates
Apr 21, 2026
Medlive Technology Co., Ltd. has convened its annual general meeting for 15 May 2026 in Beijing, where shareholders will review the audited financial statements for the year ended 31 December 2025 and vote on a proposed final dividend. The meeting...
Medlive Technology Delivers Double-Digit Revenue Growth in 2025 on Precision Marketing Strength
Mar 26, 2026
Medlive Technology reported solid growth for the year ended 31 December 2025, with revenue rising 15.0% year-on-year to RMB642.2 million, driven mainly by a 16.0% increase in its core precision marketing and corporate solutions segment. Gross prof...
Medlive Technology Declares Final 2025 Dividend for Hong Kong Shareholders
Mar 26, 2026
Medlive Technology Co., Ltd. has proposed a final ordinary dividend of RMB 0.1435 per share for the financial year ended 31 December 2025, equivalent to HKD 0.1629 per share based on an exchange rate of RMB 1 to HKD 1.1352. The payout, subject to ...
Medlive Moves to Modernize Governance With Paperless, Digital Shareholder Framework
Mar 26, 2026
Medlive Technology Co., Ltd. plans to revise its existing memorandum and articles of association to align with recent changes to Hong Kong’s Listing Rules, focusing on expansion of the paperless listing regime. The proposed changes include a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.